Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity
Press Release Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity LOS ANGELES, Calif., October 16, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceuticalcompany pioneering first-in-class therapeutics that restore synapses to improve the lives ofpatients worldwide, […]
FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism
PRESS RELEASE FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism Milestone Highlights Urgent Need for a Novel Therapeutic to Treat People with FXS FDA Designation Enables Expedited Clinical Development and Regulatory Review Timelines for SPG601 LOS ANGELES, Jan. 13, 2025 /PRNewswire/ — Spinogenix, […]
Spinogenix Appoints American Football Hall of Famer and Health Advocate Steve Young to its Board of Directors
Press Release Spinogenix Appoints American Football Hall of Famer and Health Advocate Steve Young to its Board of Directors LOS ANGELES, Calif., November 25, 2024—Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of people worldwide, today announced the appointment of Steve Young, hall of fame former quarterback […]
Spinogenix Announces Launch of Glaucoma Program and Addition of World-Renowned Expert Dr. Robert Weinreb to its Science Advisory Board
Press Release Spinogenix Announces Launch of Glaucoma Program and Addition of World-Renowned Expert Dr. Robert Weinreb to its Science Advisory Board LOS ANGELES, Calif., October 16, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceuticalcompany pioneering first-in-class therapeutics that restore synapses to improve the lives ofpatients worldwide, today announced that Dr. Robert N. Weinreb, MD, has joined […]
Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia
Press Release Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia Phase 2 trial is designed to evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia LOS ANGELES, Calif., September 25, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceuticalcompany pioneering first-in-class […]
Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease
Press Release Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease SPG302 is a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive function in people with Alzheimer’s disease LOS ANGELES, Calif., August 1, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class […]
Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 Fragile X syndrome
Press Release Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X syndrome U.S. FDA has granted Orphan Drug Designation to SPG601 for the Treatment of Fragile X SPG601 is a novel small molecule that works by correcting specific synaptic dysfunctions in the brain to address core symptoms of Fragile […]
Spinogenix Announces Approval from the Australia Human Research Ethics Committee to Initiate a Phase 2 Human Clinical Trial of SPG302 for the Treatment of Alzheimer’s Disease
Press Release Spinogenix Announces Approval from the Australia Human Research Ethics Committee to Initiate a Phase 2 Human Clinical Trial of SPG302 for the Treatment of Alzheimer’s Disease Phase 2 study is designed to evaluate the safety, tolerability, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate Alzheimer’s disease. SPG302 is also being evaluated in […]
Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS
Press Release Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS SPG302 is being developed as a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive and motor function in people with ALS LOS ANGELES, Calif., May 29, 2024 — Spinogenix, Inc., a […]
Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X syndrome
Press Release Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X syndrome Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X syndrome LOS ANGELES, Calif., May 20, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics […]
